A single-use bioreactor for adhesive cell culture, ideal for AAV and LV vector production. Scalable from research and development to commercial production!
The iCELLis® single-use bioreactor is an integrated high-density cell culture bioreactor that combines the advantages of single-use technology and fixed-bed bioreactors to simplify processes. Designed with a focus on rapid setup and ease of use, this compact system allows for a cell adhesion area of 4 square meters in a benchtop system, and commercial production systems can achieve a maximum culture area of 500 square meters with just 3.2 square meters of footprint! It enables cell seeding at lower densities (1000 cells/cm² for Vero cells), significantly reducing manual labor and associated costs by simplifying the process. **Features** - Simplification of the process from pre-culture to product - Integrated single-use bioreactor - Rapid process development due to simple structure - Linear scalability from research and development to actual production - High cell density achieves reduced volume and increased productivity compared to traditional tank stirred bioreactors *For more details, please refer to the PDF document or feel free to contact us.*
Inquire About This Product
basic information
【Functions and Configuration】 ■ Uniform circulation of culture medium through a low shear stress internal stirring mechanism ■ Macro carriers optimized for cell adhesion ■ High oxygen supply efficiency due to a distinctive waterfall mechanism ■ Ensures process reliability with a single-use bioreactor made of USP Class VI compliant plastic ■ Fixed bed ranging from 2 to 10 cm, compatible with various scales *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Purpose】 ■iCELLis(R) Nano System: For research and development, small-scale culture (up to 4m2) ■iCELLis(R) 500+ System: For production scale (up to 500m2) *For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
![[Case Study] Amplification Efficiency of Bacteriophages](https://image.mono.ipros.com/public/product/image/6b6/2001482584/IPROS88095834412701813365.png?w=280&h=280)
